Solactive launches Pharma & Biotech Opportunities Index

Related Content Related Articles

Solactive AG has launched the Solactive Pharma & Biotech Opportunity Index, which will be used as underlying by Societe Generale Corporate & Investment Banking (SG CIB) for an Open End Certificate targeting IFAs as well as clients in retail and private banking based both in Germany and Austria.

The Solactive Pharma & Biotech Opportunity Index aims to capture growth of the consolidating pharmaceutical and biotechnology healthcare industry, through companies which are potential targets of M&A activity.

Steffen Scheuble, CEO at Solactive, said: “Being close to the market, following the latest trends and launching first of their kinds indices is key to an Index Provider. The Solactive Pharma & Biotech Opportunity Index is a great example of an innovative idea with a huge potential — tracking stocks in the growing pharma & biotech industry whose price would benefit from the premium paid if they do get acquired.”

Peter Bösenberg, director and head of Public Distribution Germany & Austria at SG CIB ads: “Through the new Open End Certificate on the Pharma & Biotech Opportunity-Index, Investors have an interesting opportunity to benefit from the increasing M&A Activity in terms of the consolidation of the Pharma & Biotech Industry.”

ABOUT THE AUTHOR
Mona Dohle
Mona Dohle speaks German and Dutch, she is DACH & Benelux Correspondent for InvestmentEurope. Prior to that, she worked as a journalist in Egypt and Palestine. She started her career as a journalist working for a local German newspaper. Mona graduated with an MSc in Development Studies from SOAS and has completed the CISI Certificate in International Wealth and Investment Management.

Read more from Mona Dohle

preloader
Close Window
View the Magazine





You need to fill all required fields!